Navigation Links
Study Links the Risk of Hypogonadism in Men to Long Acting Opioids in Patients Using Daily Opioid Therapy for Chronic Noncancer Pain
Date:2/24/2012

levels were taken from each man referred to the clinic that was currently on daily opioid therapy for chronic noncancer pain. The study found that 57 percent of men were hypogonadal overall, but that 74 percent (34/46) of men on long-acting opioids were hypogonadal. Of the men on short-acting opioids, 34 percent (12/35) were hypogonadal, which was statistically significant at p<0.001. The study defined hypogonadism as a total AM testosterone <250 ng/dl.

Using a multivariate analysis correcting for dose, the study found that patients on a long-acting opioid formulation had a 4.78 greater odds of becoming hypogonadal, than did patients on an equivalent dose of a short-acting opioid formulation (95% confidence interval 1.51-15.07, p = 0.008). The study also found that dose was not significantly associated with hypogonadism in the multivariate model.

Although the study was not large enough to examine the differences between specific drugs, a subsequently awarded grant is currently underway to study men across the Kaiser Northern California System on opioids who had their testosterone levels checked. Dr. Rubinstein hopes to see a prospective study examining this question in the future.

About AAPM
The American Academy of Pain Medicine is the premiere association for 2,400 pain physicians and their treatment teams. Now in its 28th year of service, the Academy's mission is to optimize the health of patients in pain and eliminate it as a major public health problem by advancing the practice in the specialty of pain medicine. More information is available at www.painmed.org.


'/>"/>
SOURCE American Academy of Pain Medicine
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2. Preclinical Study Examines Use of nContacts Technology in Enabling a Percutaneous Device Approach to Epicardial Ablation
3. CHPA Responds to Prescription Mandate Cost Implications Outlined in Oklahoma Economic Impact Study
4. Medical Device Study Examines Use of Emerging Markets and Outsourcing for Clinical Activities
5. Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932
6. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
7. Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
8. SCOLR Pharmas Partner to Commence Bioequivalence Study of Ondansetron
9. Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
10. Zimmer and ISTO Technologies Announce Phase III Clinical Study to Evaluate the Effectiveness of Engineered Juvenile Cartilage to Repair Damaged Knees
11. Aria Diagnostics Announces Name of New Non-Invasive Prenatal Assay - Harmony Prenatal Test™ - and Publication of Study on Specimen Transport
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... -- CVS Health Corporation (NYSE: CVS ) will ... 2015, at 8:30 a.m. (EDT) with analysts and investors ... An audio webcast of the conference call will be ... CVS Health website for all interested parties. To access ... be archived and available on the web site for ...
(Date:4/17/2015)... , April 17, 2015 ... EGFR mutation   is a viable alternative to tumour biopsy ... testing in all patients with advanced NSCLC   ... effectiveness of plasma circulating tumour DNA (ctDNA) testing for epidermal ... with advanced non-small cell lung cancer (NSCLC) in clinical practice. ...
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... the "Mammography Equipment - Global Strategic Business Report" ... analyzes the worldwide markets for Mammography Equipment in US$ ... and Digital Mammography Equipment. The report provides separate comprehensive ... Japan , Europe ...
Breaking Medicine Technology:"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 2"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 3"Real World" Data Support Use of Blood Test for EGFR Mutation in Advanced NSCLC 4Mammography Equipment (Analog & Digital) Market 2015-2020 - Global Strategic Business Report: Breast Imaging Screening Programs Push Sales 2
... BioVex Inc, a company developing next generation biologics ... announced today that the results from a Phase I/II combination ... will be presented at the 2009 American Society of Clinical ... 2009 - June 2, 2009 in Orlando, FL. The results ...
... on BIBW 2992, an Irreversible, Dual EGFR / HER2 ... NSCLC Patients with EGFR Activating Mutations - (1,2)-The First ... Conn., May 14 Boehringer Ingelheim will present new ... 2992 and BIBF 1120 at the 2009 Annual Meeting ...
Cached Medicine Technology:BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 2BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 3BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 2Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 3Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 4Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 5Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 6Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 7Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 8Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 9Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009 10
(Date:4/18/2015)... (PRWEB) April 18, 2015 “ ArcAngel ” ... which takes a look at the latest and coolest ... Joe Troohey, the host of AppWatch and technology expert, conducted ... a personal safety app. , In a turbulent world, ... help. Calling 911 should always be their first move, but ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... April 17, 2015 ERGO-Pedic Products, LLC, ... introducing two new products to help a broader range ... pain relief are the second most common visitors to ... product, designed specifically to help relieve sitting pain. Then, ... and thousands of happy customers later, we began getting ...
(Date:4/17/2015)... Florida Hospital Wesley Chapel, Florida Hospital at ... were all selected as Top Workplaces in Tampa Bay. ... is ranked number one for large businesses according to ... in partnership with an independent research firm. Florida Hospital ... opened in October of 2012 with a vision of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
Breaking Medicine News(10 mins):Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Seat Cushion Company Credits Customer Driven Design For Two New Products 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3
... system of this mosquito is of great importance as scientists ... of viruses that cause yellow and dengue fevers ... genes that make up the immune system of the Aedes ... been identified. ,This study is the first of ...
... the airplane, is about to be connected, allowing travellers to ... off cell phones and fasten seatbelts are a familiar ... European company has found a way to make dialling safe ... ,"Cabin connectivity is here and GSM phone use is both ...
... a healthy diet rich in fish and nuts could be ... to prostate cancer, new US research indicates . A study ... Investigation found that omega-3 fatty acids found in the foods ... to the condition. Working with mice genetically engineered to develop ...
... an ancient retrovirus that infected chimps and other primates millions ... species is susceptible to HIV, said a study released Thursday. ... against a four-million-year-old virus, called Pan troglodytes endogenous retrovirus, or ... most retroviruses, it inserts its DNA into the genome of ...
... urate in the blood is linked to a reduced risk ... at the Harvard School of Public Health (HSPH), was led ... ,Urate is a normal component of blood, and although ... beneficial effects because it is a potent antioxidant. ...
... Thursday said that all villages affected by chikungunya fever ... spread awareness among people even as 17,000 suspected ... this year. ,'We have asked the nine chikungunya-affected ... National Rural Health Mission, we will provide Rs.10,000 each ...
Cached Medicine News:Health News:Aedes Agypti Mosquitos Immune System Revealed 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 2Health News:'Hi, can You Hear Me? I'm at 30,000 Feet' 3Health News:Ancient Viral Defense may Explain Susceptibility to HIV: Study 2Health News:High Urate Levels in Blood Linked to Reduced Parkinson's Risk 2Health News:Chikungunya-hit Villages to Get Funds to Fight Mosquitoes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: